Natural killer (NK) cells are immune cells. NK cell therapy investigates ways to use these cells against cancer. It is a different treatment category from mesenchymal stem cell therapy, and the terms NK, CAR NK and CAR T do not describe the same product.
On this page
What are NK cells and CAR NK therapy?
NK cells are part of the immune system and can recognise and kill certain abnormal cells. Researchers can collect and prepare NK cells for treatment. CAR NK approaches genetically modify them with a chimeric antigen receptor designed to recognise a particular target on cancer cells.
CAR T uses T cells, another immune cell type. An approval or trial result for CAR T cannot be assumed to apply to CAR NK. The cell source, engineering and target all matter. MD Anderson: understanding CAR NK therapy.
What does the research show?
A 2024 report from MD Anderson described a phase I/II study of cord-blood-derived CD19-targeted CAR NK cells in 37 people with selected B-cell malignancies. It reported encouraging responses, but this was a specific investigational product in a defined cancer population.
Those findings do not validate every NK preparation, establish a benefit in healthy people or show that the same approach works for solid tumours. Larger and longer studies help clarify which patients benefit and how outcomes compare with other care. MD Anderson: phase I/II CD19 CAR NK trial results (2024).
Who should assess suitability?
Start with the oncology team responsible for your cancer care. The relevant questions include the exact diagnosis, disease stage, previous treatment, current disease activity and whether a matching study or authorised treatment exists. A general immune-cell package cannot answer those questions.
For an initial discussion, prepare the pathology report, recent imaging reports, treatment history and current medication list. Ask how records can be shared securely. Do not delay or stop recommended cancer treatment while seeking another opinion.
Compare the proposal with the complete treatment plan. Immunotherapy is one cancer-treatment category; its suitability and risks depend on the individual approach. National Cancer Institute: immunotherapy.
Questions about an NK protocol
- Are the cells unmodified NK cells or an engineered CAR NK product?
- What is the cell source, and which tumour target is involved?
- Which evidence matches my cancer and prior treatments?
- Is this an authorised use or a clinical trial in Thailand?
- Is preparatory treatment required, and what are its separate risks?
- Who provides emergency care and long-term follow-up?
Ask for the written protocol summary and consent information. If it is a trial, request the registry identifier and contact the named study team to confirm eligibility and access. A registry entry alone is not proof of approval or available places.
Risks, follow-up and costs
Do not interpret an encouraging safety result from one small trial as proof that all NK products are risk-free. Ask the treating team to distinguish risks from the cells, any preparatory medicines and other treatment given alongside them. Obtain the protocol-specific adverse-event information.
Request written instructions for urgent symptoms and an emergency contact. People receiving cancer treatment should follow their oncology team’s instructions for fever or sudden illness; breathing difficulty, collapse or new confusion needs immediate assessment.
A written estimate should identify assessment, cell preparation, associated medicines, hospital care, monitoring and follow-up. Clarify what is research-funded, what you pay and who manages care after travel.
Frequently asked questions
Is NK cell therapy a stem cell treatment?
NK cells are immune cells. Some products may originate from donor or stem-cell-derived manufacturing systems, but the administered NK treatment is distinct from an MSC infusion.
Can it prevent cancer or boost immunity in a healthy person?
The cancer trial described here does not establish either claim. Ask for clinical outcome evidence in the population and use being proposed.
Is it the same as dendritic cell therapy?
No. NK approaches use cancer-killing immune cells; dendritic cell approaches aim to help direct an immune response by presenting antigens.
Does this clinic offer NK therapy?
This page provides information, not confirmation of service availability. Ask about specialist assessment and the exact proposed protocol before arranging travel or payment.
Ask about an assessment
Contact Thailand Stem Cell Clinic to ask about the review process, current availability and how to share relevant records. Confirm the responsible clinician, proposed treatment and follow-up arrangements before booking.
Browse all treatment guides · Understand evidence levels
Sources
- MD Anderson: understanding CAR NK therapy
- MD Anderson: phase I/II CD19 CAR NK trial results (2024)
- National Cancer Institute: immunotherapy
General educational information, not an individual treatment recommendation. A clinician who knows your history should assess your options. External sources describe their own products, research and jurisdictions; they do not establish availability or authorisation at this clinic.